Treatment of patients with asthma during COVID-19

Good management of patients with bronchial asthma protects against SARS-CoV-2 infection, which is associated with the activity limiting the virus penetration into the respiratory epithelial cells. A relationship between asthma exacerbation and SARS-CoV-2 infection has not yet been demonstrated. The available recommendations state that patients with asthma should use inhaled glucocorticosteroids (GCS) on a regular basis. In the case of exacerbation of asthma symptoms, it is necessary to administer higher doses of inhaled GCSs and to quickly add systemic GCSs, mainly methylprednisolone. Treatment with biological preparations does not increase the risk of SARS-CoV-2 infection, and is effective in reducing the number of asthma exacerbations.